Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab SC vs IV + Pom/Dex in RRMM
NCT04045795Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2019
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, open-label trial of isatuximab in multiple myeloma (MM) (5 arms), sponsored by Sanofi. Primary endpoints: Assessment of adverse events, Pharmacokinetic assessment: Ceoi and 7 more. Started Aug 2019; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04045795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045795.